TRIO and hereditary hemorrhagic telangiectasia: Although we originally investigated activation of Vegf-Trio as a means to augment arterial diameter in the context of improving perfusion for ischemic cardiovascular disease, the notion that inhibiting Trio and reducing EC and arterial size, may have therapeutic relevance as well for preventing shunt formation and vascular complications in, for example hereditary hemorrhagic telangiectasia (HHT)10,11.